Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.64) by 25 percent. This is a 51.02 percent increase over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $64.864 million which missed the analyst consensus estimate of $70.439 million by 7.91 percent. This is a 223.64 percent increase over sales of $20.042 million the same period last year.